Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 |
| clinicaltrials |
| NCT05790096 | Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy | unknown | Phase 3 | 60 | Blau Farmaceutica S.A.INDUSTRY | 0 | Mar 29, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT00412022 | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.(HOBOE) | unknown | Phase 3 | 1,294 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer(MITO-7) | unknown | Phase 3 | 800 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05783882 | Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma(FLAT) | unknown | Phase 3 | 114 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05620355 | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | unknown | Phase 3 | 312 | Bio Genuine (Shanghai) Biotech Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT04924699 | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 / Phase 3 | 350 | Shanghai Miracogen Inc.INDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03846362 | A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML | unknown | Phase 3 | 500 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05753865 | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | unknown | Phase 3 | 454 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05728632 | Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines(CONTROL) | unknown | Phase 3 | 80 | Giulio StefaniniOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05739630 | M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia | unknown | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05720026 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | unknown | Phase 3 | 560 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05244577 | Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer | unknown | Phase 3 | 75 | Shi YanxiaOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02914158 | Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women(ASPAIT) | unknown | Phase 3 | 680 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05670054 | Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients | unknown | Phase 3 | 116 | Mansoura UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03863223 | A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | unknown | Phase 3 | 590 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT00887380 | STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)(STARS) | unknown | Phase 3 | 2,023 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04106999 | Dexmedetomidine and HIPEC | unknown | Phase 2 / Phase 3 | 20 | University of British ColumbiaOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05103644 | Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients" | unknown | Phase 2 / Phase 3 | 60 | Beni-Suef UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2023source: clinicaltrials